Chapter title |
Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays
|
---|---|
Chapter number | 34 |
Book title |
Exon Skipping and Inclusion Therapies
|
Published in |
Methods in molecular biology, September 2018
|
DOI | 10.1007/978-1-4939-8651-4_34 |
Pubmed ID | |
Book ISBNs |
978-1-4939-8650-7, 978-1-4939-8651-4
|
Authors |
Ralph Slijkerman, Hannie Kremer, Erwin van Wijk, Slijkerman, Ralph, Kremer, Hannie, Wijk, Erwin van |
Abstract |
Antisense oligonucleotide (AON)-based splice modulation has been proven to hold great promise as a therapeutic strategy for a number of hereditary conditions. AONs are small modified single-stranded RNA or DNA molecules that are complementary to splice enhancer or silencer target sites. Upon pre-mRNA binding, AONs will prevent or stimulate binding of the spliceosome thereby modulating splicing events. AONs can be designed and applied for different genes and genetic disorders as the specificity depends on their nucleotide sequence. Here we provide a guideline for setting up AON-based splice-modulation experiments by describing a detailed protocol to design and evaluate AONs using a combination of in silico and in vitro analyses. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 23% |
Researcher | 2 | 15% |
Unspecified | 1 | 8% |
Professor | 1 | 8% |
Other | 1 | 8% |
Other | 2 | 15% |
Unknown | 3 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 6 | 46% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
Unspecified | 1 | 8% |
Agricultural and Biological Sciences | 1 | 8% |
Medicine and Dentistry | 1 | 8% |
Other | 0 | 0% |
Unknown | 3 | 23% |